Comparative Pharmacology
Head-to-head clinical analysis: PARADIONE versus VALRELEASE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PARADIONE versus VALRELEASE.
PARADIONE vs VALRELEASE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Paradione (paramethadione) is an oxazolidinedione anticonvulsant that suppresses neuronal activity in the motor cortex by increasing the threshold for repetitive neuronal firing and reducing synaptic transmission. Its exact mechanism is unclear but involves modulation of T-type calcium channels and enhancement of GABAergic inhibition.
Increases GABAergic transmission by inhibiting GABA transaminase and blocking voltage-gated sodium channels.
100 mg orally three times daily; maximum 600 mg/day.
500 mg orally twice daily, extended-release formulation. Maximum dose: 2000 mg/day.
None Documented
None Documented
12-24 hours (terminal); prolonged in renal impairment
Terminal elimination half-life is 6-16 hours (mean 10.6 h) in adults; shorter at 4-12 h in children due to enhanced clearance; prolonged to 12-18 h in hepatic impairment or elderly. Clinical context: Once-daily dosing requires extended-release formulation (Valrelease) to maintain trough levels.
Renal: 70% unchanged; biliary/fecal: 25%; metabolic: 5%
Renal: 70-80% as metabolites (valproic acid glucuronide, 3-oxo-valproate, 2-en-valproate) and <3% unchanged. Hepatic: 15-20% via bile into feces. Other: 1-3% exhaled as CO2.
Category C
Category C
Anticonvulsant
Anticonvulsant